

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Klaus STOCKEMANN et al.

SERIAL NO: 09/117,357

FILING DATE: September 22, 1998

FOR: PHARMACEUTICAL COMBINED PREPARATION AND ITS USE IN THE TREATMENT OF
INAECOLOGICAL DISORDERS

GAU: 1654

EXAMINER: C. Delacroix-Muirheid

OCT 30 2001
 U.S. PATENT & TRADEMARK OFFICE
 ASSISTANT COMMISSIONER FOR PATENTS
 WASHINGTON, D.C. 20231

AMENDMENT TRANSMITTAL

TECH CENTER 1600/2900

NOV 02 2001

SIR:

Transmitted herewith is an amendment in the above-identified application.


- No additional fee is required.
- Applicant(s) is/are entitled to small entity status.
- Additional documents filed herewith:

The fee has been calculated below:

CLAIMS	CLAIMS REMAINING		HIGHEST NO. PREVIOUSLY PAID FOR	NO. OF EXTRA CLAIMS	RATE	CALCULATIO NS
TOTAL	22	MINUS	25	5	x \$18 =	\$00.00
INDEPENDENT	5	MINUS	3	0	x \$84 =	\$168.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS						\$0.00
TOTAL OF ABOVE CALCULATIONS						\$0.00
<input type="checkbox"/>						
<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY						\$0.00
<input type="checkbox"/> RECORDATION OF ASSIGNMENT						\$0.00
						TOTAL
						\$168.00

- A check in the amount of \$168.00 and 2 Month Extension of Time for \$400.00 is attached.
- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.
- If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. § 1.136, and any additional fees required under 37 C.F.R. § 1.36 for any necessary extension of time may be charged to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


 Brion P. Heaney, Registration No. 32,542
 Attorney for Applicants
MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
 Arlington Courthouse Plaza I
 2200 Clarendon Blvd. Suite 1400
 Arlington, Virginia 22201
 Telephone: (703) 243-6333
 Facsimile: (703) 243-6410
 Date: October 30, 2001
 BPH:imm\Amend Transm 10-30-01

RECEIVED


RECEIVED

NOV 02 2001

21/11/2001

TECH CENTER 1600/2900

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE



In re Application of:

Klaus STÖCKEMANN et al.

Art Unit: 1654

Serial No.: 09/117,357

Examiner: C. Delacroix-Muirheid

Filed: September 22, 1998

Title: PHARMACEUTICAL COMBINED PREPARATION AND ITS USE IN THE TREATMENT OF GYNAECOLOGICAL DISORDERS

REPLY

Sir:

In response to the Office Action of June 4, 2001, please amend the above identified application as follows:

IN THE CLAIMS:

Please delete claims 15, 16, 21, 22 and 41.

Please amend the following claims as follows:

--30. (Amended) A method according to claim 34, wherein said LHRH analogue is administered in the amount of 2 µg-20 mg per kilogram of body weight and Raloxifene is administered in an amount of 0.1 µg-10 mg per kilogram of body weight.

34. A method for ameliorating LHRH analogue-induced reduction in bone density in a patient comprising administering to said patient one or more LHRH analogues and Raloxifene wherein said one or more LHRH analogues and Raloxifene are administered sequentially or simultaneously.

35. A method according to claim 34, wherein said LHRH analogue is Leuprorelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂, Ramorelix, Zoladex or combinations thereof.